LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Shin, Jung Young ^a   Kim, Jeong Oh ^a   Lee, Suk K ^a   Chae, Hiun Suk ^b   Kang, Jin Hyoung ^c  

^a The Catholic University of Korea   (South Korea)

^b Uijeongbu St Mary's Hospital   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 2; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; SMALL INTERFERING RNA; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC ANTIMETABOLITE; CHROMONE DERIVATIVE; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; ENZYME INHIBITOR; MATRIX PROTEIN; MESSENGER RNA; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; EPSTEIN BARR VIRUS INFECTION; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN EXPRESSION; STOMACH CANCER; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; EPSTEIN BARR VIRUS; GENETICS; METABOLISM; MITOCHONDRION; PATHOGENICITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR CELL CULTURE; VIROLOGY; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMONES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; EPSTEIN-BARR VIRUS INFECTIONS; FLUOROURACIL; HERPESVIRUS 4, HUMAN; HUMANS; MITOCHONDRIA; MORPHOLINES; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; VIRAL MATRIX PROTEINS;

EID: 77955495968     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-425     Document Type: Article

References (34)

1. Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 1992, 140:769-774. 1886378, 1314023.
2. Fukayama M. Epstein-Barr virus and gastric carcinoma. Pathol Int 2010, 60(5):337-50. 10.1111/j.1440-1827.2010.02533.x, 20518883.
3. Israel BF, Kenney SC. Virally targeted therapies for EBV-associated malignancies. Oncogene 2003, 22:5122-130. 10.1038/sj.onc.1206548, 12910249.
4. Jung E, Lee Y, Lee B, Chang M, Kim W. Ganciclovir augments the lytic induction and apoptosis induced by chemotherapeutic agents in an Epstein-barr virus-infected gastric carcinoma cell line. Anti-Cancer Drugs 2007, 18:79-5.
5. Portis T, Longnecker R. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/AKT pathway. Oncogene 2004, 23:8619-8. 10.1038/sj.onc.1207905, 15361852.
6. Young LS, Rickinson AB. EPSTEIN-ARR VIRUS: 40 YEARS ON. Nature Rev 2004, 4:757-768.
7. Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998, 16:3158-3168.
8. Shiao Y, Rugge M, Correa P, et al. p53 alteration in gastric precancerous lesions. Am J Pathol 1994, 144:511-17. 1887105, 8129036.
9. Ojima H, Fukuda T, Nakajima T, et al. Infrequent overexpression of p53 protein in Epstein-Barr virus associated gastric carcinomas. Jpn J Cancer Res 1997, 88:262-6.
10. Leung SY, Chau KY, Yuen ST, et al. p53 overexpression is different in Epstein-Barr virus-associated and Epstein-Barr virus-negative carcinoma. Histopathology 1998, 33(4):311-317.
11. Kume T, Oshima K, Shinohara T, et al. Low rate of apoptosis and overexpression of bcl-2 in Epstein-Barr virus-associated gastric carcinoma. Histopathology 1999, 34:502-9. 10.1111/j.1365-2559.1999.00686.x, 10383694.
12. Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996, 274:784-787. 10.1126/science.274.5288.784, 8864119.
13. Camp ER, Li J, Minnich DJ, Brank A, Moldawer LL, MacKay SLD, Hochwald SN. Inducible Nuclear Factor-B Activation Contributes to Chemotherapy Resistance in Gastric Cancer. J Am Coll Surg 2004, 199:249-258. 10.1016/j.jamcollsurg.2004.04.015, 15275881.
14. Cardone MH, Roy N, Stennicke H, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998, 282:1318-1. 10.1126/science.282.5392.1318, 9812896.
15. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. AKT promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-8. 10.1016/S0092-8674(00)80595-4, 10102273.
16. Curnock AP, Logan MK, Ward SG. Chemokine signalling: Pivoting around multiple phosphoinositide 3-kinases. Immunology 2002, 105:125-136. 10.1046/j.1365-2567.2002.01345.x, 1782650, 11872087.
17. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NFκB. J Clin Inves 2001, 107:241-246.
18. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the AKT serine-threonine kinase. Nature 1999, 401:82-5. 10.1038/43466, 10485710.
19. Feng WH, Israel B, Raab-Traub N, Busson P, Kenney SC. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive tumors. Cancer Res 2002, 62:1920-6.
20. Feng WH, Hong G, Delecluse HJ, Kenney SC. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 2004, 78:1893-1902. 10.1128/JVI.78.4.1893-1902.2004, 369434, 14747554.
21. Portis T, Dyck P, Longnecker R. Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003, 102:4166-4178. 10.1182/blood-2003-04-1018, 12907455.
22. Portis T, Longnecker R. Epstein-Barr virus LMP2A interferes with global transcription factor regulation when expressed during B-lymphocyte development. J Virol 2003, 77:105-114. 10.1128/JVI.77.1.105-114.2003, 140618, 12477815.
23. Tanaka M, Kawaguchi Y, Yokofujita J, Takagi M, Eishi Y, Hirai K. Sequence variations of Epstein-Barr virus LMP2A gene in gastric carcinoma in Japan. Virus Genes 1999, 19:103-111. 10.1023/A:1008171006400, 10541014.
24. Ohtsu A. Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 2005, 8:95-102. 10.1007/s10120-005-0324-9, 15864716.
25. Leong T. Chemotherapy and radiotherapy in the management of gastric cancer. Curr Opin Gastroenterol 2005, 21:673-678. 10.1097/01.mog.0000179833.28158.b7, 16220043.
26. Jung E, Lee Y, Lee B, Chang M, Kim W. Lytic induction and apoptosis of Epstein-Barr virus-associated gastric cancer cell line with epigenetic modifiers and ganciclovir. Cancer Letters 2007, 247:77-83. 10.1016/j.canlet.2006.03.022, 16647201.
27. Zhang X, Yashiro M, Ohira M, Ren J, Hirakawa K. Synergic, antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma. Cancer Sci 2006, 97(9):938-44. 10.1111/j.1349-7006.2006.00253.x, 16805821.
28. Lee K, Kim S, et al. Enzastaurin, a Protein Kinase Cβ Inhibitor, Suppresses Signaling through the Ribosomal S6 Kinase and Bad Pathways and Induces Apoptosis in Human Gastric Cancer Cells. Cancer Res 2008, 68(6):1916-1926. 10.1158/0008-5472.CAN-07-3195, 18339873.
29. Zhang X, Yashiro M, Qiu H, Nishii T, Matsuzaki T, Hirakawa K. Establishment and characterization of multidrug-resistant gastric cancer cell lines. Anticancer Res 2010, 30(3):915-21.
30. Oki E, et al. AKT phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 2005, 117:376-80. 10.1002/ijc.21170, 15900596.
31. Gibson S, Tu S, Oyer R, Anderson SM, Johnson GL. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis, Requirement for AKT activation. J Biol Chem 1999, 274(25):17612-8. 10.1074/jbc.274.25.17612, 10364198.
32. Moody CA, Scott RS, Amirghahari N, Nathan CA, Young LS, Dawson CW, Sixbey JW. Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. J Virol 2005, 5499-5506. 10.1128/JVI.79.9.5499-5506.2005, 1082717, 15827164.
33. Park SY, et al. Expression of P53, Bcl-2, Bax, and P-glycoprotein in Relation to Chemotherapeutic Response in Patients with Advanced Non-Small-Cell Lung Cancer. J Korean Cancer As soc 2001, 33(2):158-162.
34. Gulley ML, Pulitzer DR, Eagan PA, Schneider BG. Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation. Hum Pathol 1996, 27(1):20-7. 10.1016/S0046-8177(96)90133-1, 8543306.